CCR2 and neoplasm: A lack of CCR2 expression on HSPCs reduces splenic myelopoiesis, impairs the suppression activity of tumor MDSCs, allows an increase in the number of tumor-infiltrating IFNγ+CD3+CD8+ CTLs, and enhances immunotherapy efficacy (37, 38).